Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4) Antibody (APC)

Este producto es parte de FLT4 -  fms related receptor tyrosine kinase 4
Product Graph
689€ (100 tests)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4) Antibody (APC)
category
Primary Antibodies
provider
Abbexa
reference
abx270723
tested applications
FCM

Description

Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4) Antibody (APC) is a Rabbit Polyclonal Antibody conjugated to APC against Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4) for use in flow cytometry.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Vascular Endothelial Growth Factor Receptor 3 / VEGFR3 (FLT4)
Host
Rabbit
Reactivity
Mouse
Recommended Dilution
FCM: 1-5 µl/106 cells. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
APC
Isotype
IgG
Purification
Purified by antigen-specific affinity chromatography.
Size 1
100 tests
Size 2
200 tests
Size 3
500 tests
Form
Liquid
Tested Applications
FCM
Buffer
0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.
Availability
Please enquire.
Storage
Aliquot and store at 2°C to 8°C upon receipt. Avoid exposure to light.
Dry Ice
No
Alias
PCL,CHTD7,FLT-4,FLT41,LMPH1A,LMPHM1,VEGFR3,VEGFR-3,Tyrosine-protein kinase receptor FLT4,Fms-like tyrosine kinase 4,Vascular endothelial growth factor receptor 3
Background
Antibody anti-FLT4
Status
RUO

Descripción

Fms related receptor tyrosine kinase 4 (FLT4) FLT4, also known as vascular endothelial growth factor receptor 3 (VEGFR3), is a receptor tyrosine kinase critical for the regulation of lymphangiogenesis, the formation of lymphatic vessels. Structurally, FLT4 comprises an extracellular domain with seven immunoglobulin-like loops, a single transmembrane domain, and an intracellular tyrosine kinase domain. FLT4 binds VEGF-C and VEGF-D ligands, leading to receptor dimerization and activation of downstream signaling pathways, including the MAPK and PI3K-AKT cascades. These pathways are essential for lymphatic endothelial cell proliferation, migration, and survival. FLT4 is predominantly expressed in lymphatic endothelial cells, where it plays a pivotal role in maintaining lymphatic vessel integrity and fluid homeostasis. Dysregulation of FLT4 has been linked to lymphedema, a condition characterized by lymphatic fluid accumulation, and its overexpression has been implicated in cancer progression, where it promotes tumor lymphangiogenesis and metastasis. FLT4 is a promising therapeutic target for modulating lymphatic function in both pathological and developmental contexts.

Related Products

EH0729

Human FLT4 (Vascular endothelial growth factor receptor 3) ELISA Kit

Ver Producto
EM0206

Mouse VEGFR3/FLT4 (Vascular Endothelial Cell Growth Factor Receptor 3) ELISA Kit

Ver Producto
ER0238

Rat Flt4 (Vascular endothelial growth factor receptor 3) ELISA Kit

Ver Producto